

# Advancements in diagnostic medicine: A comprehensive review of emerging technologies and techniques

Peter Stefanic<sup>1</sup>, Ghizal Fatima<sup>2</sup>, Jan Fedacko Fedacko<sup>3</sup>, Abbas Ali Mahdi<sup>4</sup>

<sup>1</sup>CLINIC OF VASCULAR SURGERY, THE EAST SLOVAK INSTITUTE OF CARDIOVASCULAR DISEASES, FACULTY OF MEDICINE, PAVOL JOZEK SAFARI UNIVERSITY, KOSICE, SLOVAKIA

<sup>2</sup>DEPARTMENT OF BIOTECHNOLOGY, ERA'S MEDICAL COLLEGE AND HOSPITAL, ERA UNIVERSITY, LUCKNOW, INDIA

<sup>3</sup>DEPARTMENT OF GERONTOLOGY AND GERIATRIC, MEDIPARK, UNIVERSITY RESEARCH PARK, PJ SAFARIK UNIVERSITY, KOSICE, SLOVAKIA

<sup>4</sup>DEPARTMENT OF BIOCHEMISTRY, ERA'S MEDICAL COLLEGE AND HOSPITAL, ERA UNIVERSITY, LUCKNOW, INDIA

## ABSTRACT

**Aim:** The integration of newly developing technologies is driving a transformative shift in diagnostic medicine by enhancing the speed, accuracy, and personalization of disease diagnosis. Traditional diagnostic methods, such as radiography, histology, and biochemical testing, often face limitations in efficiency, sensitivity, and specificity. This review aims to explore recent advancements in diagnostic tools and techniques.

**Materials and Methods:** This review examines the latest developments in diagnostic medicine, including digital pathology, molecular diagnostics, and wearable technologies. Digital pathology enables the digitization of slides and the application of Artificial Intelligence (AI) for precise and timely diagnoses, particularly in oncology. Advances in molecular diagnostics, such as genomic and proteomic profiling, are evaluated for their role in improving disease detection and monitoring. The study also highlights emerging trends in telemedicine, personalized medicine, and precision medicine.

**Conclusions:** Recent technological innovations are revolutionizing diagnostic medicine, offering unprecedented opportunities to enhance healthcare delivery. Digital pathology and molecular diagnostics are setting new standards for accuracy and efficiency, while wearable technologies and telemedicine are expanding access to personalized care. These advancements underscore the transformative potential of integrating cutting-edge technologies into diagnostic practices, paving the way for a future of more effective and patient-centered healthcare.

**KEY WORDS:** molecular diagnostics, digital pathology, emerging technologies, artificial intelligence.

Wiad Lek. 2025;78(10):2180-2192. doi: 10.36740/WLek/211528 DOI

## INTRODUCTION

The landscape of diagnostic medicine is evolving rapidly, driven by advances in technology and an increasing demand for more accurate, efficient, and personalized healthcare solutions. Diagnostic medicine plays a pivotal role in the healthcare system, serving as the cornerstone for disease detection, management, and monitoring. Traditionally, diagnostic techniques such as histopathology, radiology, and biochemical tests have been the mainstays of clinical diagnostics. These methods, while invaluable, have inherent limitations in terms of sensitivity, specificity, and the time required to obtain results. As the complexity of diseases increases and the emphasis on personalized medicine grows, the need for innovative diagnostic approaches has become increasingly apparent. Histopathology and cytology, long considered the gold standard for diagnosing various conditions, including cancer, involve the microscopic examination of tissue samples [1]. These techniques, which include modalities like computed tomography (CT), magnetic resonance imaging (MRI),

and X-ray, offer non-invasive visualization of internal structures and have revolutionized the ability to detect and monitor a wide range of conditions, but they are also time-consuming and heavily dependent on the subjective interpretation of pathologists, which can lead to variability in diagnoses. These imaging methods do have certain drawbacks, though, such as the possibility of false positives or negatives and the occasional exposure to ionizing radiation. Furthermore, the sensitivity and specificity required for an early diagnosis or the detection of pathogens are sometimes lacking from biochemical assays and microbiological diagnostics, which analyze blood and other physiological fluids to discover biomarkers or infections [2].

A surge of cutting-edge technologies is revolutionizing diagnostic medicine in response, opening up new possibilities for more accurate, quick, and customized diagnosis. One example of a game-changer is digital pathology, which makes it possible to digitize pathology slides and integrate them with artificial intelligence (AI) for remote analysis and improved diagnostic accuracy.

The development of AI algorithms that may help detect patterns and anomalies that the human eye might overlook is made easier by this technology, which also simplifies the workflow for pathologists. Artificial intelligence (AI) is being used more and more in medical imaging to help diagnose and characterize diseases like cancer, cardiovascular disease, and neurological problems. Its applications in diagnostic medicine go beyond digital pathology [3].

The field of molecular diagnostics has advanced by making it possible to identify diseases at the genetic and molecular levels. Genetic alterations are being identified, illness development is being tracked, and more individualized treatment choices are being made thanks to methods like polymerase chain reaction (PCR), next-generation sequencing (NGS), and CRISPR-based diagnostics [4]. In oncology, where targeted therapy response may be predicted by identifying specific genetic alterations through molecular diagnostics, these developments are especially noteworthy. The advent of point-of-care testing (POCT) has brought diagnostic capabilities closer to the patient, facilitating quick testing and instantaneous results—important in emergency situations and the management of long-term conditions. Another frontier in diagnostic medicine is nanotechnology, which provides extremely precise and sensitive diagnostic instruments. By identifying biomarkers at incredibly low concentrations, nano-biosensors and nanoparticles are being developed for the early diagnosis of illnesses, including cancer. These technologies allow for non-invasive testing and real-time tracking of the course of disease in addition to increasing diagnosis accuracy [5].

These new technologies have a lot of potential, but there are a few obstacles to overcome before they can be fully incorporated into clinical practice. It is necessary to address ethical issues including data privacy and the possibility of bias in AI systems. Regulations must also change to keep up with technology developments in order to guarantee that newly developed diagnostic instruments are secure and useful for patient care. Another important factor to consider is the expense of putting these technologies into practice and making sure they are accessible, especially in areas with limited resources [6]. By facilitating earlier detection, more precise diagnoses, and individualized treatment plans, advances in diagnostic medicine have the potential to significantly improve patient outcomes. These technologies will surely be crucial in determining the direction of healthcare in the future as they develop, providing new avenues for enhancing the standard and efficiency of diagnostic services.

## AIM

The purpose of this review is to provide a concise and structured overview of the transformative impact of emerging technologies on diagnostic medicine. It aims to highlight the limitations of traditional diagnostic methods and emphasize the advancements offered by innovations such as digital pathology, molecular diagnostics, and wearable technologies.

## MATERIALS AND METHODS

This review was conducted through a comprehensive analysis of recent advancements in diagnostic medicine, focusing on peer-reviewed literature, clinical studies, and technological reports published between 2015 and 2024. The primary areas of investigation included:

digital pathology, molecular diagnostics, and wearable technologies. Digital pathology enables the digitization of slides and the application of Artificial Intelligence (AI) for precise and timely diagnoses, particularly in oncology. Advances in molecular diagnostics, such as genomic and proteomic profiling, are evaluated for their role in improving disease detection and monitoring. The study also highlights emerging trends in telemedicine, personalized medicine, and precision medicine.

## CONVENTIONAL DIAGNOSTIC TECHNIQUES: A SYNOPSIS

Traditional techniques like histology, cytology, radiography, blood testing, and microbiological diagnostics have long been a part of diagnostic medicine. These methods have been the foundation of medical diagnostics, offering vital data for the identification, diagnosis, and treatment of a wide range of illnesses. These techniques do, however, have several drawbacks that may compromise their overall accuracy, sensitivity, and specificity despite their widespread application and proven effectiveness. An outline of these conventional diagnostic techniques is given in this section, together with an emphasis on their advantages and disadvantages.

## HISTOPATHOLOGY AND CYTOLOGY

The microscopic analysis of tissues to investigate disease symptoms is known as histopathology. It is regarded as the gold standard for identifying many different diseases, including malignancies. On the other hand, histopathology studies individual cells or groups of cells by processing, staining, and microscopic examination of a surgical or biopsy specimen in order to find cellular abnormalities, tissue architecture, and other pathological

traits suggestive of illnesses. Pap smears are frequently used in cytology to screen for cervical cancer, and fine needle aspiration cytology (FNAC) is a common method for analysing lumps and abnormalities in different tissues. Cytology can be utilized for early disease identification and screening, and it is less invasive than histopathology. Although cytology and histopathology are effective diagnostic methods, they have drawbacks. The pathologist's experience and the sample's quality have a major impact on these procedures' accuracy. Misdiagnosis can result from sampling problems, such as collecting an inadequate or non-representative specimen. Furthermore, these methods take a lot of time because they include processing tissue, staining, and microscopic inspection, which can take hours or even days. Additionally adding to the heterogeneity is the subjective interpretation, which could compromise the consistency of the diagnosis [7].

## RADIOLOGY (X-RAY, CT, MRI)

A variety of non-invasive imaging techniques, including as CT, magnetic resonance imaging, and X-rays, are included in the field of radiology. These techniques enable the observation of internal structures. X-rays are frequently used to find tumors, infections, and fractures. CT scans help diagnose complex illnesses such internal bleeding, tumors, and cardiovascular diseases by providing more comprehensive cross-sectional images of the body. MRI is a powerful diagnostic tool for neurological problems, musculoskeletal conditions, and certain malignancies due to its superior soft-tissue contrast. The primary benefit of using them is their capacity to offer non-invasive, real-time insights into the interior architecture of the body, which aids in early diagnosis and directs treatment choices. These techniques do have certain drawbacks, though. Ionizing radiation, which is exposed to during X-rays and CT scans, is normally minimal but has the potential to cause cancer if exposure is sustained or repeated. Even though MRIs are less radiation-intensive, they are costly, time-consuming, and shouldn't be done on those who have specific implants or claustrophobia. Furthermore, radiological imaging occasionally produces false positives or negatives, which can cause misunderstandings. For instance, benign lesions could be misdiagnosed as malignant tumors, or small, early-stage malignancies could go undiscovered, particularly if inadequate contrast or image resolution makes it difficult to see them [8, 9].

## BLOOD TESTS AND BIOCHEMICAL ANALYSIS

Among the most widely used diagnostic instruments are blood tests, which offer vital details regarding an

individual's general health, organ function, and the existence of disease. Complete blood counts (CBCs), liver and kidney functions, and glucose levels are among the common blood tests. Diagnosing diseases including diabetes, liver disease, and cardiovascular illnesses requires the use of biochemical studies, which count the levels of hormones, lipids, enzymes, and other indicators. Since many biomarkers are non-specific, they might be elevated under a variety of circumstances, making it challenging to determine the precise origin of the aberration. Increased C-reactive protein (CRP) levels, for instance, may be a sign of inflammation, but there are many other possible underlying causes for this, including infections and long-term conditions like rheumatoid arthritis. Furthermore, blood tests frequently only record the body's condition at a specific moment in time, making it difficult to completely understand how a disease progresses or how the body reacts to therapy [10].

## MICROBIOLOGICAL DIAGNOSTICS

Identification of pathogens, including bacteria, viruses, fungi, and parasites that cause infectious disorders, is a key component of microbiological diagnosis. Culture, microscopy, serology, and molecular techniques such as polymerase chain reaction (PCR) are among the techniques used. When diagnosing bacterial infections, culture methods where pathogens are cultivated on certain media are regarded as the gold standard. Serological tests identify antigens or antibodies linked to infectious pathogens, indicating past or present illnesses. (11) Microbiological diagnostics can have certain limitations, though. There are diseases that are hard to grow or that need specific conditions and media, which can result in false negatives. Even while serological testing is quicker, it might not be able to distinguish between an ongoing infection and a previous exposure since antibodies might linger long after an infection has healed. Furthermore, even though PCR and other molecular techniques are very sensitive, they can require expensive equipment and knowledge, which makes them inaccessible in environments with limited resources [12].

## LIMITATIONS OF TRADITIONAL METHODS

Traditional diagnostic techniques have improved patient outcomes and advanced medical knowledge, but they are not without drawbacks. Timely and accurate diagnosis can be hampered by their reliance on invasive techniques, subjective interpretation, and laborious processes. Furthermore, the inability of many

conventional techniques to identify diseases at the molecular level restricts their capacity to offer individualized therapy options. More sophisticated diagnostic methods that can get beyond these restrictions and provide higher sensitivity, specificity, and speed are therefore becoming more and more necessary [13]. More accurate, timely, and individualized diagnostic options are being made available by the development of digital pathology, molecular diagnostics, and other cutting-edge technology. These new innovations are not only enhancing the accuracy of detection of diseases but also paving the way for the integration of diagnostics into a more personalized and predictive healthcare model.

## EMERGING TECHNOLOGIES IN DIAGNOSTIC MEDICINE: DIGITAL PATHOLOGY

### OVERVIEW AND BENEFITS

Utilizing state-of-the-art technology, digital pathology is a breakthrough development in diagnostic medicine that improves the effectiveness, precision, and accessibility of pathological examinations. Digital pathology is essentially the process of taking, analysing, and storing high-resolution photographs of tissue samples using digital imaging and computational tools. With the use of digital slide scanning and image analysis, manual microscopy and glass slide processing are replaced by this technology [14]. The main advantages of digital pathology are several. First off, by giving pathologists high-resolution images that can be enlarged and thoroughly examined, it improves diagnostic accuracy. Because of the enhanced visibility, diseased characteristics can be seen more precisely, which could result in more accurate diagnosis. Second, digital pathology makes it easier for medical practitioners to collaborate. Digital image sharing between pathologists and colleagues in different places allows for in-the-moment consultations and second opinions. This ability to work together can enhance the results of diagnosis, especially in complicated circumstances. Digital pathology also increases process productivity. [15] It can take a lot of time to perform traditional microscopy because pathologists have to physically handle and inspect many glass slides. This procedure is streamlined by digital pathology, which provides quick image access for review and diagnosis. Additionally, digitizing slides creates a permanent, readily available record of pathology cases, which is beneficial for research and long-term studies.

The goal of personalized medicine is to adjust medical care to each patient's unique set of traits, including

lifestyle, genetic, and environmental influences. This method relies heavily on digital pathology, which offers precise, high-quality images that may be combined with other data sources to improve treatment and diagnosis plans. Pathologists can correlate molecular and genetic data with histopathological findings by using digital pathology. For example, precise digital pictures of tumor samples can be analysed along with genomic information to find particular mutations or biomarkers that guide focused treatments. With this integration, treatment strategies can be more effectively and individually tailored based on the distinct molecular profile of each patient's condition. Furthermore, by facilitating extensive data analysis, digital pathology advances precision medicine. In conventional diagnostic settings, patterns and correlations could go unnoticed. However, high-throughput imaging and data analytics might reveal them. This method can open the door to novel treatments and more accurate illness management techniques by providing fresh insights into the mechanisms underlying disease and how treatments work [16].

Digital pathology is changing as a result of the incorporation of AI and machine learning, which is advancing the field's efficiency and accuracy in diagnosis. Digital pathology photos can be analysed by AI algorithms to find patterns and anomalies that might be signs of a disease. For instance, pathologists can identify and quantify abnormal features more accurately by using machine learning models that have been trained to identify malignant cells or other features with high precision. Workflow automation is further improved by AI and machine learning. Large amounts of data can be processed fast using automated image analysis, which minimizes the human work needed for slide review and interpretation. In addition to speeding up the diagnostic procedure, this automation reduces the possibility of human error, producing more consistent and trustworthy results. Predictive analytics powered by AI can also help personalized medicine by predicting possible treatment outcomes based on past data and image analysis. These prediction models can assist medical professionals in choosing the best courses of action for specific patients, maximizing therapeutic results, and reducing side effects. When combined with AI and machine learning, digital pathology represents a major advancement in diagnostic medicine. It opens the door for more efficient and customized patient care by improving diagnostic accuracy, streamlining workflows, and supporting specific treatment plans [17]. As these technologies develop further, their combination promises to completely transform the area and open up new avenues for the diagnosis and treatment of complicated illnesses.

## REVIEW

### MOLECULAR DIAGNOSTICS: GENOMIC AND PROTEOMIC PROFILING IN CANCER DIAGNOSTICS

Medicine is being revolutionized by molecular diagnostics, especially in the identification and management of cancer. Through an emphasis on the molecular and genetic basis of diseases, this field provides more accurate, individualized, and successful treatment and diagnostic choices. At the vanguard of these developments are critical technologies like next-generation sequencing (NGS), CRISPR, and genomic and proteomic profiling. These tools enable more individualized treatment strategies and offer comprehensive insights into the molecular causes of cancer.

### GENOMIC AND PROTEOMIC PROFILING

Using genomic profiling, one can find genetic mutations, variances, or aberrations linked to cancer by analysing a cell's entire genome. This method makes it possible to pinpoint the precise mutations that fuel the onset, spread, and resistance of cancer to therapy. These genetic alterations can be found throughout the entire genome or just in the sections of the genome that code for proteins, respectively, using methods like whole-genome sequencing (WGS) and whole-exome sequencing (WES). On the other hand, proteomic profiling is concerned with the thorough examination of proteins expressed by an organism, tissue, or cell. Since the majority of biological functions are powered by proteins, a study of the proteome landscape of a malignant cell can offer crucial insights about the behaviour, course, and response to therapy of the disease. Proteomic profiling commonly uses mass spectrometry and protein microarrays to identify and quantify proteins and their changes, which are frequently changed in cancer [18].

Comprehending the intricate biology of cancer requires an understanding of both proteomic and genomic profiling. They make it possible to identify molecules known as biomarkers that can be used to identify cancer, forecast the course of a disease, and track an individual's reaction to treatment. Proteomic analysis has identified proteins like HER2, which is overexpressed in certain types of breast cancer and is targeted by therapies like trastuzumab. Similarly, the identification of mutations in the BRCA1 and BRCA2 genes has led to targeted therapies for breast and ovarian cancers [19].

### APPLICATIONS IN CANCER DIAGNOSTICS

The way that tumors are identified and categorized has changed as a result of the incorporation of proteomic

and genomic profiling into cancer diagnostics. Conventional diagnostic techniques, like histopathology, frequently depend on the anatomical and morphological features of malignancies. Molecular diagnostics, on the other hand, offers a more thorough and precise categorization according to the genetic and molecular features of the tumor. For instance, more individualized treatment plans have been made possible by the molecular subtyping of breast cancer into subtypes like HER2-positive, hormone receptor-positive, and triple-negative, which has improved patient outcomes. Similar to this, the discovery of certain mutations in lung cancer - like ALK, ROS1, and EGFR rearrangements - has prompted the creation of targeted treatments that, when compared to conventional chemotherapy, greatly increase patient survival. Furthermore, molecular diagnostics makes liquid biopsies easier to use for early cancer diagnosis. By analysing circulating tumor DNA (ctDNA) or other indicators in blood samples, these non-invasive diagnostics make it possible to detect cancer early on, when it is more likely to be treatable. Liquid biopsies have a number of advantages over conventional biopsy techniques, including the ability to track the advancement of a disease and its response to treatment in real-time [20].

### CRISPR AND NEXT-GENERATION SEQUENCING

A potent genome editing technology called CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has been modified for use in diagnostics. With CRISPR, targeted mutations or genome repairs can be made to validate the involvement of particular genes in carcinogenesis and identify them in cancer. With great specificity and sensitivity, CRISPR-based diagnostics, like CRISPR-Cas9, can also identify particular genetic abnormalities linked to cancer. [21] Another ground-breaking tool in molecular diagnostics is next-generation sequencing (NGS). With NGS, millions of DNA fragments may be sequenced simultaneously, giving a complete picture of a tumor's genetic makeup. It is especially useful for figuring out which genomic changes, such as copy number variations and genetic mutations, cause cancer. Comprehensive genomic profiling of cancers has been made possible by NGS, which has allowed for the discovery of therapeutically useful mutations and the creation of individualized treatment regimens. Precision oncology - where treatments are customized to the unique genetic composition of each patient's tumor - is being made possible by the combination of CRISPR and NGS in molecular diagnostics. This strategy lowers the chance of side effects while simultaneously

increasing treatment efficacy since medicines can be tailored to precisely target the genetic changes that the cancer has. At the vanguard of cancer diagnostics is molecular diagnostics, which uses CRISPR, next-generation sequencing, genomic and proteomic profiling, and other techniques. Patient outcomes are greatly improved by these technologies, which make it possible to diagnose and treat cancer in a way that is more precise, individualized, and efficient. With continued development, these instruments could lead to even more breakthroughs in precision medicine, which could eventually result in improved cancer treatment and even possible cures [22].

### **POINT-OF-CARE TESTING (POCT): ADVANCEMENTS IN RAPID DIAGNOSTICS AND PORTABLE DEVICES**

Medical diagnostic testing carried out at or close to the location of patient care is referred to as “point-of-care testing” (POCT). Rapid and accurate test findings are made possible by this method, which enhances patient outcomes and helps clinicians to make decisions more quickly. POCT is becoming more and more popular because of its capacity to offer prompt feedback, which lessens the need for centralized laboratory testing and improves the effectiveness of healthcare delivery. Rapid Diagnostic Tests (RDTs) and portable diagnostic equipment are just two examples of the many technologies that make up POCT, and they are essential for treating both chronic illnesses and infectious infections.

### **RAPID DIAGNOSTIC TESTS (RDTs)**

Quick and dependable results are produced by RDTs, a subset of POCT, frequently in a matter of minutes. In locations with limited access to complete laboratory equipment, like remote or resource-poor areas, these tests are especially helpful. RDTs are frequently utilized in the diagnosis of COVID-19, HIV, and malaria, among other infectious disorders. They usually only require a basic technique that can be done with little training, including using a nose swab or blood drop. By facilitating early identification and treatment, RDTs have completely changed the landscape of infectious illnesses, slowing the spread of illness and enhancing patient outcomes. For instance, RDTs enable the quick detection of malaria cases in malaria-endemic areas, guaranteeing timely treatment and lessening the strain on healthcare systems. Similar to this, during the COVID-19 pandemic, the extensive use of RDTs for antigen detection enabled mass testing and prompt isolation of positive individuals, which significantly aided in containing the virus’s spread [23, 24].

### **ROLE IN INFECTIOUS DISEASES AND CHRONIC CONDITIONS**

POCT is useful not only in the treatment of infectious diseases but also in the management of long-term illnesses such as diabetes, heart disease, and renal disease. For improved disease control and lower risk of complications, POCT devices such as glucometers enable patients receiving diabetic treatment to check their blood glucose levels at home. In a similar vein, portable blood pressure monitors and cholesterol testing kits are vital resources for cardiovascular disease management since they let patients monitor their status and instantly modify their lifestyle [25]. POCT enhances patient participation and treatment protocol adherence in the setting of chronic illnesses. POCT gives patients the tools they need to actively control their health by giving them prompt feedback. This is especially crucial for the long-term care of chronic illnesses. Additionally, POCT makes it possible for medical professionals to promptly modify treatment strategies in light of real-time data, which eventually improves patient outcomes [26].

### **PORTABLE DIAGNOSTIC DEVICES**

For POCT, the advent of portable diagnostic instruments has changed everything. These gadgets are made to be small, easy to use, and quick to deliver precise results. Wearable biosensors, handheld ultrasonography instruments, and portable ECG monitors are a few examples. These devices are perfect for use in a range of contexts, such as ambulances, home care, and isolated areas, because of their portability. Additionally important in emergency medicine, when prompt decision-making can save lives, are portable diagnostic tools. For example, trauma victims can be evaluated in ambulances using portable ultrasound equipment, which helps doctors decide on therapy before the patient ever gets to the hospital. Similar to this, portable ECG monitors can offer quick information about a patient’s cardiac condition, enabling early intervention in the event of an arrhythmia or heart attack. POCT is transforming healthcare by offering fast and precise diagnostic information through the use of portable diagnostic equipment and RDTs. It plays a vital role in the management of chronic illnesses and infectious infections, providing prompt diagnosis, improved patient outcomes, and improving the effectiveness of healthcare delivery, particularly in environments where traditional laboratory services are scarce. POCT will remain crucial to the provision of healthcare around the world as technology develops [27].

## ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIAGNOSTICS

Medical diagnostics is changing as a result of AI and machine learning (ML), which improve disease detection and prognosis accuracy, efficiency, and speed. These technologies use enormous volumes of data to create complex algorithms that can recognize patterns and make predictions that are more accurate than those of a human. Predictive analytics, AI-powered diagnostic tools, and AI applications in pathology and imaging are leading this transformation and greatly enhancing patient outcomes.

### AI-DRIVEN DIAGNOSTIC TOOLS

AI-driven diagnostic technologies are intended to help medical professionals make more accurate disease diagnoses. These tools make use of machine learning algorithms that have been trained on large datasets, such as imaging data, test findings, and medical records. AI may identify minute patterns and connections in this data that human experts might overlook, enabling earlier and more precise diagnosis. AI algorithms are used to analyse retinal images and detect early indicators of diabetic retinopathy, one prominent example of which is this disease. It has been demonstrated that these AI systems can reach accuracy levels that are on par with or even higher than those of human specialists. In a similar vein, AI technologies are being created to diagnose respiratory disorders, cardiovascular ailments, and skin cancer, allowing for a quicker and more accurate diagnosis of these conditions [28].

### PREDICTIVE ANALYTICS IN DIAGNOSTICS

With the help of AI and ML, predictive analytics forecasts future health outcomes by utilizing historical data. Predictive analytics in diagnostics enables early intervention and improved condition management by identifying individuals who are susceptible to specific diseases before symptoms manifest. Predictive models, for example, are used in oncology to determine the chance of a cancer recurrence based on patient information such as genetic profiles and treatment histories [29]. By allowing clinicians to more carefully monitor patients and tailor treatment strategies, these models increase the likelihood of positive outcomes. Predictive analytics can identify people who are at risk of complications in chronic diseases like diabetes, allowing for preventative actions to avert serious health problems. The prognosis after a hemorrhagic stroke is typically inaccurate. In order to assist in guiding treatment decisions and assessing patient prognosis, several AI

rating measures have been developed to help forecast outcomes for patients who have had intracerebral haemorrhages (ICH) [30]. Furthermore, population health management uses AI-driven predictive analytics to spot patterns and anticipate infectious disease epidemics. AI can assist public health authorities in responding more efficiently to emerging health hazards by analysing data from several sources, such as social media, healthcare records, and environmental data streams.

### AI IN IMAGING AND PATHOLOGY

AI has a particularly significant impact on pathology and medical imaging. AI algorithms are employed in imaging to improve the interpretation of CT, MRI, ultrasound, and X-ray images, hence increasing the precision of disease identification. For instance, in radiology, AI can recognize lung nodules in CT scans that might be signs of early-stage lung cancer, even if human vision finds them difficult to discern. Artificial Intelligence is transforming tissue sample analysis in pathology. The physical, subjective, and time-consuming examination of slides under a microscope is the foundation of traditional pathology. Digital pathology solutions with AI capabilities can accurately evaluate whole-slide images, detecting malignant cells, classifying tumors, and forecasting patient outcomes. This technique decreases human error and expedites the diagnosis procedure, resulting in more reliable results. AI is also making it possible to create next-generation instruments, such virtual biopsies, which evaluate imaging data to determine whether disease is present without requiring invasive procedures. The development of AI-driven pathology and imaging is accelerating, improving, and reducing the invasiveness of diagnostic procedures. With the advent of AI-driven technologies, predictive analytics, and enhanced imaging and pathology solutions, machine learning and artificial intelligence are completely changing the diagnostics industry. These innovations are improving the precision of diagnoses, making early detection possible, and customizing patient care. AI will become more and more important in enhancing healthcare outcomes and changing the diagnostic environment as it develops [31].

### NANOTECHNOLOGY IN DIAGNOSTICS

With its revolutionary instruments for early disease detection and accurate diagnosis, nanotechnology is being used more and more in the diagnostics industry. Researchers have created nano-biosensors, nanoparticles, and tailored diagnostic methods with previously unheard-of sensitivity and specificity by modifying

materials at the nano-scale. These developments are revolutionizing the diagnosis process by facilitating earlier identification and more precise evaluations, which eventually improve patient outcomes.

## NANO-BIOSENSORS AND NANOPARTICLES

Early disease diagnosis is made possible by highly sensitive devices called nano-biosensors, which identify biological substances at the nanoscale. Typically, these sensors use nanoparticles tiny particles with a diameter of one to one hundred nanometers to improve their sensitivity and selectivity. Because of their special qualities, nanoparticles may interact at the molecular level with biological systems, which makes them perfect for identifying biomarkers linked to a variety of disorders. For instance, because of their exceptional conductivity and biocompatibility, gold nanoparticles are frequently utilized in nano-biosensors. In order to target and bind to disease-specific biomarkers, such as proteins or nucleic acids, found in biological fluids like blood or saliva, these nanoparticles can be functionalized with particular antibodies or DNA sequences. Once the biomarker binds to the nanoparticle, the nano-biosensor releases a detectable signal, indicating the presence of the disease at an early stage [32].

## APPLICATIONS IN EARLY DETECTION OF DISEASES

One of the most exciting uses of nanotechnology in medicine is its ability to identify diseases, especially cancer, early [33]. Conventional diagnostic techniques frequently identify illnesses after symptoms manifest, which might restrict available treatments and lower survival rates. Long before symptoms appear, diseases can be identified at the molecular level thanks to nanotechnology. For instance, nanoparticles can be designed to target particular cancer cells or tumor markers in the context of cancer diagnosis. After being injected, these nanoparticles travel throughout the body and gather inside the tumor, where they may be seen with fluorescence or magnetic resonance imaging. This method increases the likelihood of a favourable outcome by detecting cancer in its earliest stages. Similarly, nano-biosensors are developed to detect the biomarkers for cardiovascular diseases, neurological disorders, and infectious diseases. These sensors can detect minute concentrations of disease-specific molecules, enabling early diagnosis and prompt intervention of diseases, which is crucial for conditions where early treatment significantly improves outcomes [34].

## TARGETED DIAGNOSTIC TECHNIQUES


Targeted diagnostic methods are also made possible by nanotechnology, and they provide more accurate illness diagnosis. Targeted nano-diagnostics are intended to engage selectively with diseased tissues or cells, minimizing injury to healthy tissues, in contrast to standard diagnostic approaches that may involve intrusive procedures or expose patients to high doses of radiation. MRI is one application where magnetic nanoparticles are used. By functionalizing these nanoparticles to target particular tissues or cells, MRI scans can be made more accurate in identifying cancers or other abnormalities by improving contrast. This focused strategy decreases the likelihood of false positives and minimizes the need for repeat imaging in addition to improving diagnostic accuracy. Nanoparticles that have been designed to bind to particular pathogens or toxins can also be used in the diagnosis of infectious disorders. By identifying the infectious agent with greater speed and accuracy, this targeted detection helps to stop the disease from spreading and enables for prompt treatment. Through the development of specialized diagnostic procedures, nanoparticles, and nano-biosensors, nanotechnology is transforming the field of diagnostics. By enabling earlier and more precise illness detection, these advancements enhance patient outcomes and progress the area of customized medicine. Future developments in nanotechnology will have a significant impact on how diagnostic medicine is practiced [35].

The main developments in diagnostic medicine are shown in Figure 1 along with how they affect patient outcomes. The first ones are AI-Driven Diagnostic Tools, which use predictive analytics to improve diagnostic accuracy and enable early disease detection in imaging and pathology. Advances in nanotechnology, such as tailored diagnostic methods and nano-biosensors, make early disease detection and accurate diagnosis easier. Genomic and proteomic profiling, enables customized treatment regimens and molecular diagnostics. This results in more efficient, specialized care. By concentrating on portable diagnostic tools and remote patient monitoring, telemedicine and remote diagnostics aim to increase access to healthcare, particularly in underprivileged areas. These developments result in earlier and more precise diagnosis, better treatment customisation, and increased accessibility, forming a future that is more effective and efficient.

## LIMITATIONS AND DIFFICULTIES OF NEW DIAGNOSTIC TECHNOLOGIES

Emerging diagnostic technologies, like molecular diagnostics, nanotechnology, and artificial intelligence,





**Fig. 1.** The main developments in diagnostic medicine  
*Source: Own materials*

present a number of obstacles and constraints as they become more widely used in healthcare. These include issues with data privacy and ethics, obstacles related to regulations, challenges integrating the technology into clinical practice, and queries about accessibility and cost-effectiveness. To guarantee that new technologies can be used in healthcare in a safe and efficient manner, it is imperative that these issues are resolved.

**ETHICAL CONCERNS AND DATA PRIVACY**  
The ethical ramifications of using modern diagnostic technology are one of the main issues they present. For example, AI-driven diagnoses sometimes call for the gathering and examination of enormous volumes of patient data. Concerns around permission, data privacy, and the possible misuse of private health information are brought up by this. The increasing reliance of healthcare systems on digital platforms raises serious concerns about breaches and illegal access to sensitive health data. To preserve patient trust and protect privacy, it is essential to make sure that patient data is stored securely and that strong consent procedures are

in place. Additionally, there may be moral conundrums involving decision-making if AI is used in diagnostics. For example, it can be difficult to decide which AI system to believe if its diagnosis differs from a human doctor's. The possibility that AI will reinforce prejudices found in the training data, creating inequities in healthcare results, exacerbates this predicament [36].

**REGULATORY CHALLENGES**  
New diagnostic technologies are developing faster than regulatory agencies can assess and authorize them. One of the regulatory obstacles lies in ensuring that these technologies satisfy strict requirements for quality, safety, and efficacy before to being released onto the market. For example, in order to demonstrate their accuracy and dependability, AI-driven tools and diagnostics based on nanotechnology need to go through extensive testing. The intricacy and originality of these technologies, however, complicate the application of conventional regulatory procedures. Clear and uniform regulatory frameworks that are flexible enough to change with the rapidly developing nature

of these technologies are also necessary. The approval and acceptance of novel diagnostic instruments are frequently delayed by current laws because they are unable to keep up with the rapid pace of invention. This can hinder the timely availability of potentially life-saving technologies to patients [37].

## INTEGRATION INTO CLINICAL PRACTICE

There are several obstacles to overcome when incorporating cutting-edge diagnostic technologies into routine clinical practice. It will take time, money, and a change in customs to train healthcare professionals to use these new instruments. Furthermore, because AI and nanotechnology frequently need for new IT infrastructure, equipment, and procedures, incorporating them into current healthcare workflows can be challenging. Healthcare workers who could be wary of using AI-driven technologies or uninitiated with nanotechnology-based diagnostics are similarly resistant to change. Successful integration depends on making sure these technologies are easy to use and that healthcare providers are given the necessary support when implementing them [38].

## COST-EFFECTIVENESS AND ACCESSIBILITY

Emerging diagnostic technologies face major obstacles in their widespread adoption, including cost-effectiveness and accessibility. These technologies frequently have substantial development and implementation costs, even though they have the potential to improve patient outcomes and diagnostic accuracy. Because of this, healthcare systems with tight funds may not be able to access them, especially in low- and middle-income nations. Furthermore, patients may not be able to afford these technologies, which could result in unequal access to cutting-edge diagnostics. For these technologies to be widely adopted and to help reduce health disparities, it is imperative that they be both affordable and effective. In order to overcome these financial obstacles and increase the accessibility of these technologies, it may be necessary to investigate different funding options like public-private partnerships or government subsidies. Emerging diagnostic technologies provide a number of intricate and varied problems and constraints. The effective integration of these technologies into clinical practice, cost-effectiveness, regulatory obstacles, and ethical issues must all be addressed. To ensure that these advances can be used safely and effectively to improve patient care, coordination between healthcare professionals, regulators, technology developers, and legislators will be necessary to overcome these challenges [39].

## DISCUSSION

The integration of these technologies into diagnostic medicine represents a significant leap forward in healthcare. However, their successful implementation requires addressing key challenges, including cost, accessibility, and ethical considerations related to data privacy. Collaboration between researchers, clinicians, and policymakers will be essential to harness the full potential of these innovations [36]. By bridging the gap between traditional methods and advanced technologies, diagnostic medicine is poised to deliver more precise, efficient, and patient-centered care. This evolution underscores the need for continuous research, investment, and education to prepare healthcare systems for a technology-driven future.

A few crucial areas are set to influence the direction of healthcare in the future as diagnostic technology continues to advance. At the forefront of this transition are advances in wearable diagnostics, telemedicine and remote diagnostics, personalized and precision medicine, and collaborative interdisciplinary approaches that promise to improve patient outcomes. Precision and personalized medicine emphasizes adjusting medical care to each patient's unique needs. More accurate diagnostic instruments that can recognize genetic variants, estimate the risk of disease, and direct specialized treatment regimens are becoming possible because to developments in genomics, proteomics, and bioinformatics. Taking into account each patient's distinct genetic composition not only increases therapeutic efficacy but also minimizes unwanted effects. The delivery of healthcare is being completely transformed by the growth of telemedicine and remote diagnostics. Patients can now obtain medical consultations and diagnostic services from the comfort of their homes thanks to developments in digital health technologies. AI-powered remote diagnostics enable ongoing health state monitoring and early problem detection through connected devices. This is especially helpful for treating chronic illnesses and giving underprivileged or isolated communities access to healthcare [40].

Another exciting area in healthcare is wearable diagnostics. Heart rate, blood sugar, and oxygen saturation are just a few of the many health metrics that can be tracked in real-time by gadgets like smart-watches, fitness trackers, and biosensors. These gadgets offer early warning indicators for possible health problems in addition to continuous health monitoring, allowing for prompt action and better patient outcomes. The use of interdisciplinary and collaborative approaches will also influence the future of diagnostics. It is imperative to include knowledge from domains like bioengineering, data science, and clinical medicine in order to create

novel diagnostic instruments and guarantee their successful application. The translation of state-of-the-art research into useful applications will be fuelled by collaboration between academic institutions, business, and healthcare providers, and will ultimately result in more precise and easily accessible diagnostics [40]. Customized medicine, telemedicine, wearable diagnostics, and collaborative methodologies have the potential to revolutionize diagnostic medicine by enabling more accessible, accurate, and patient-centered therapy in the future. These approaches and technology will become increasingly important as healthcare develops, enhancing patient outcomes and changing the field of medical diagnostics.

## CONCLUSIONS

Key developments like molecular diagnostics, nanotechnology, AI-driven technologies, and the fusion of precision and customized medicine are causing a radical change in the field of diagnostic medicine. These developments are improving illness detection's speci-

ficity, speed, and accuracy, allowing for earlier diagnosis and more individualized treatment plans. There could be a significant effect on patient outcomes. Healthcare professionals may monitor patients' statuses more successfully, detect diseases at an earlier stage, and tailor treatment regimens based on the unique characteristics of each patient with more precise diagnostics. Through the prevention of illness development and avoidance of needless therapies, this not only raises survival rates and improves quality of life but also lowers healthcare expenditures. Future trends in diagnostic medicine point to a greater uptake of wearable technology, telemedicine, and remote diagnostics as ways to improve patient accessibility and satisfaction. Innovation will continue to be fueled by collaborative and interdisciplinary efforts, guaranteeing that new diagnostic tools are not only cutting edge in terms of technology but also useful and easily available. These developments will have a significant impact on the direction of healthcare in the future as they are incorporated into clinical practice, improving patient outcomes and developing a more effective and efficient diagnostic system.

## REFERENCES

1. Wurcel V, Cicchetti A, Garrison L, et al. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. *Public Health Genomics*. 2019;22(1-2):8-15. doi: 10.1159/000501832. DOI
2. Smith-Bindman R, Kwan ML, Marlow EC, et al. Trends in Use of Medical Imaging in US Health Care Systems and in Ontario, Canada, 2000-2016. *JAMA*. 2019 Sep 3;322(9):843-856. doi: 10.1001/jama.2019.11456.
3. Shafi S, Parwani AV. Artificial intelligence in diagnostic pathology. *Diagn Pathol*. 2023 Oct 3;18(1):109. doi: 10.1186/s13000-023-01375-z. DOI
4. Xu J, Yang P, Xue S, Sharma B, et al. Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives. *Hum Genet*. 2019 Feb;138(2):109-124. doi: 10.1007/s00439-019-01970-5. DOI
5. Liu S, Hou Y, Li Z, Yang C, Liu G.  $\mu$ PADs on Centrifugal Microfluidic Discs for Rapid Sample-to-Answer Salivary Diagnostics. *ACS Sens*. 2023 Sep 22;8(9):3520-3529. doi: 10.1021/acssensors.3c01093. DOI
6. Ullah E, Parwani A, Baig MM, Singh R. Challenges and barriers of using large language models (LLM) such as ChatGPT for diagnostic medicine with a focus on digital pathology - a recent scoping review. *Diagn Pathol*. 2024 Feb 27;19(1):43. doi: 10.1186/s13000-024-01464-7. DOI
7. Mukhopadhyay S, Feldman MD, Abels E, et al. Whole Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical Pathology: A Multicenter Blinded Randomized Noninferiority Study of 1992 Cases (Pivotal Study). *Am J Surg Pathol*. 2018 Jan;42(1):39-52. doi: 10.1097/PAS.0000000000000948. DOI
8. Smith-Bindman R, Kwan ML, Marlow EC, Theis MK, Bolch W, Cheng S, et al. Trends in Use of Medical Imaging in US Health Care Systems and in Ontario, Canada, 2000-2016. *JAMA*. 2019 Sep 3;322(9):843-856. doi: 10.1001/jama.2019.11456. DOI
9. Expert Panel on MR Safety; Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document on MR safe practices: 2013. *J Magn Reson Imaging*. 2013 Mar;37(3):501-30. doi: 10.1002/jmri.24011. DOI
10. Meng Z, Guo S, Zhou Y, et al. Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID-19. *Sig Transduct Target Ther*. 2021 Aug 25;6(1):316. doi: 10.1038/s41392-021-00731-z. DOI
11. Fatima G, Alhmadi H, Ali Mahdi A, et al. Transforming Diagnostics: A Comprehensive Review of Advances in Digital Pathology. *Cureus*. 2021;13(10):e71890. doi:10.7759/cureus.71890. DOI
12. Bursle E, Robson J. Non-culture methods for detecting infection. *Aust Prescr*. 2016 Oct;39(5):171-175. doi: 10.18773/austprescr.2016.059. DOI
13. Fenske W, Maier SK, Blechschmidt A, Allolio B, Störk S. Utility and limitations of the traditional diagnostic approach to hyponatremia: a diagnostic study. *Am J Med*. 2010 Jul;123(7):652-7. doi: 10.1016/j.amjmed.2010.01.013. DOI

- 14 Bucur O. Emerging technologies for diagnostic pathology. *Discoveries (Craiova)*. 2015 Jun 30;3(2):e46. doi: 10.15190/d.2015.38. DOI
- 15 Bueno G, Fernández-Carrobles MM, Deniz O, García-Rojo M. New Trends of Emerging Technologies in Digital Pathology. *Pathobiology*. 2016;83(2-3):61-9. doi: 10.1159/000443482. DOI
- 16 Dexter A, Tsikritsis D, Belsey NA, Thomas SA, Venton J, Bunch J, Romanchikova M. Next Generation Digital Pathology: Emerging Trends and Measurement Challenges for Molecular Pathology. *J Molecul Pathol*. 2022; 3(3):168-181. doi: 10.3390/jmp3030014 DOI
- 17 Baxi V, Edwards R, Montalto M, Saha S. Digital pathology and artificial intelligence in translational medicine and clinical practice. *Mod Pathol*. 2022 Jan;35(1):23-32. doi: 10.1038/s41379-021-00919-2. DOI
- 18 Budhbaware T, Rathored J, Shende S. Molecular methods in cancer diagnostics: a short review. *Ann Med*. 2024 Dec;56(1):2353893. doi: 10.1080/07853890.2024.2353893. DOI
- 19 Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [updated 2023 Sep 21]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A (eds). *Seattle (WA): 1993*. 1998 Sep 4 [updated 2025 Mar 20].
- 20 Lopez-Gonzalez L, Sanchez Cendra A, Sanchez Cendra C, et al. Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice. *Medicina (Kaunas)*. 2024 Jan 17;60(1):168. doi: 10.3390/medicina60010168. DOI
- 21 Awwad SW, Serrano-Benitez A, Thomas JC, Gupta V, Jackson SP. Revolutionizing DNA repair research and cancer therapy with CRISPR-Cas screens. *Nat Rev Mol Cell Biol*. 2023 Jul;24(7):477-494. doi: 10.1038/s41580-022-00571-x. DOI
- 22 Selvakumar SC, Preethi KA, Ross K, et al. CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer. *Mol Cancer*. 2022 Mar 24;21(1):83. doi: 10.1186/s12943-022-01565-1. DOI
- 23 Onsongo SN, Otieno K, van Duijn S, et al. Performance of a rapid antigen test for SARS-CoV-2 in Kenya. *Diagn Microbiol Infect Dis*. 2022 Feb;102(2):115591. doi: 10.1016/j.diagmicrobio.2021.115591. DOI
- 24 Plebani M, Nichols JH, Luppa PB, et al. Point-of-care testing: state-of-the art and perspectives. *Clin Chem Lab Med*. 2024 Jun 17;63(1):35-51. doi: 10.1515/cclm-2024-0675. DOI
- 25 Fatima G, Mahdi F. Personalized Medicine: A Novel Approach for the Management of Hypertension. *World Heart J*. 2022;14(2):169-174.
- 26 Nichols JH. Utilizing Point-of-Care Testing to Optimize Patient Care. *EJIFCC*. 2021 Jun 29;32(2):140-144. PMID: 34421482
- 27 Macchia E, Torricelli F, Caputo M, et al. Point-Of-Care Ultra-Portable Single-Molecule Bioassays for One-Health. *Adv Mater*. 2024 Mar;36(13):e2309705. doi: 10.1002/adma.202309705. DOI
- 28 Al-Antari MA. Advancements in Artificial Intelligence for Medical Computer-Aided Diagnosis. *Diagnostics (Basel)*. 2024 Jun 15;14(12):1265. doi: 10.3390/diagnostics14121265. DOI
- 29 Sheng JQ, Hu PJ, Liu X, Huang TS, Chen YH. Predictive Analytics for Care and Management of Patients With Acute Diseases: Deep Learning-Based Method to Predict Crucial Complication Phenotypes. *J Med Internet Res*. 2021 Feb 12;23(2):e18372. doi: 10.2196/18372. DOI
- 30 Chen Y, Jiang C, Chang J, et al. An artificial intelligence-based prognostic prediction model for hemorrhagic stroke. *Eur J Radiol*. 2023 Oct;167:111081. doi: 10.1016/j.ejrad.2023.111081. DOI
- 31 Pinto-Coelho L. How Artificial Intelligence Is Shaping Medical Imaging Technology: A Survey of Innovations and Applications. *Bioengineering (Basel)*. 2023 Dec 18;10(12):1435. doi: 10.3390/bioengineering10121435. DOI
- 32 Ramesh M, Janani R, Deepa C, Rajeshkumar L. Nanotechnology-Enabled Biosensors: A Review of Fundamentals, Design Principles, Materials, and Applications. *Biosensors (Basel)*. 2022 Dec 27;13(1):40. doi: 10.3390/bios13010040. DOI
- 33 Caputo D, Quagliarini E, Coppola A, et al. Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection. *Int J Surg*. 2023 Oct 1;109(10):2934-2940. doi: 10.1097/JIS.0000000000000558. DOI
- 34 Thwala LN, Ndlovu SC, Mpofu KT, Lugongolo MY, Mthunzi-Kufa P. Nanotechnology-Based Diagnostics for Diseases Prevalent in Developing Countries: Current Advances in Point-of-Care Tests. *Nanomaterials (Basel)*. 2023 Mar 31;13(7):1247. doi: 10.3390/nano13071247 DOI
- 35 Malik S, Muhammad K, Waheed Y. Emerging Applications of Nanotechnology in Healthcare and Medicine. *Molecules*. 2023 Sep 14;28(18):6624. doi: 10.3390/molecules28186624. DOI
- 36 Yadav N, Pandey S, Gupta A, Dudani P, Gupta S, Rangarajan K. Data Privacy in Healthcare: In the Era of Artificial Intelligence. *Indian Dermatol Online J*. 2023 Oct 27;14(6):788-792. doi: 10.4103/idoj.idoj\_543\_23. DOI
- 37 Williamson SM, Prybutok V. Balancing Privacy and Progress: A Review of Privacy Challenges, Systemic Oversight, and Patient Perceptions in AI-Driven Healthcare. *Appl Sci*. 2024; 14(2):675. doi: 10.3390/app14020675 DOI
- 38 Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. *Heliyon*. 2024 Feb 15;10(4):e26297. doi: 10.1016/j.heliyon.2024.e26297. DOI
- 39 Bialas C, Bechtsis D, Aivazidou E, Achillas C, Aidonis D. A Holistic View on the Adoption and Cost-Effectiveness of Technology-Driven Supply Chain Management Practices in Healthcare. *Sustainability*. 2023; 15(6):5541. doi: 10.3390/su15065541. DOI
- 40 Lotter W, Hassett MJ, Schultz N, Kehl KL, Van Allen EM, Cerami E. Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions. *Cancer Discov*. 2024 May 1;14(5):711-726. doi: 10.1158/2159-8290.CD-23-1199. DOI

The Authors extend our sincere gratitude to Era University for their generous provision of logistics support, which greatly facilitated the execution of this article.

**CONFLICT OF INTEREST**

The Authors declare no conflict of interest

**CORRESPONDING AUTHOR**

**Ghizal Fatima**

Department of Biotechnology,  
Era's Medical College and Hospital  
Era University,  
Lucknow, India  
e-mail: ghizalfatima8@gmail.com

**ORCID AND CONTRIBUTIONSHIP**

Peter Stefani: 0000-0002-0396-3676 **D** **F**  
Ghizal Fatima: 0000-0001-8516-655X **A** **D**  
Jan Fedacko Fedacko: 0000-0002-4940-0393 **F**  
Abbas Ali Mahdi: 0000-0002-8580-9911 **A** **B** **D** **E** **F**

---

**A** – Work concept and design, **B** – Data collection and analysis, **C** – Responsibility for statistical analysis, **D** – Writing the article, **E** – Critical review, **F** – Final approval of the article

**RECEIVED:** 25.10.2025  
**ACCEPTED:** 22.08.2025

